Montecito Bank & Trust bought a new stake in Pfizer Inc. (NYSE:PFE – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 30,547 shares of the biopharmaceutical company’s stock, valued at approximately $778,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the 1st quarter valued at $27,000. Curio Wealth LLC lifted its position in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares during the period. Bayforest Capital Ltd bought a new stake in Pfizer during the first quarter worth about $28,000. Harbor Asset Planning Inc. purchased a new stake in Pfizer in the second quarter worth about $29,000. Finally, Howard Hughes Medical Institute purchased a new stake in Pfizer in the second quarter worth about $30,000. 68.36% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
PFE has been the topic of a number of analyst reports. Citigroup assumed coverage on Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target on the stock. Scotiabank began coverage on Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price on the stock. Wolfe Research set a $24.00 target price on Pfizer and gave the stock an “underperform” rating in a research note on Wednesday. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Wednesday. Finally, HSBC reissued a “buy” rating and set a $29.00 price objective on shares of Pfizer in a research report on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average price target of $28.06.
Pfizer Trading Up 0.1%
Pfizer stock opened at $25.06 on Friday. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The business’s fifty day moving average is $25.09 and its 200 day moving average is $24.82. The stock has a market capitalization of $142.48 billion, a PE ratio of 14.57 and a beta of 0.46. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97.
Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.
Pfizer Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is 100.00%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
- Five stocks we like better than Pfizer
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500
- A Deeper Look at Bid-Ask Spreads
- Forget the Chips: 4 Industrial Plays for the AI Rebound
- What is the Dogs of the Dow Strategy? Overview and Examples
- MongoDB Could Hit Record Highs—But You’ll Need to Move Fast
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
